Literature DB >> 17216555

Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Atsuo Yoshino1, Yoichi Katayama, Akiyoshi Ogino, Takao Watanabe, Kazunari Yachi, Takashi Ohta, Chiaki Komine, Takakazu Yokoyama, Takao Fukushima.   

Abstract

Aberrant hypermethylation of CpG islands in the promoter region plays a causal role in the inactivation of various key genes involved in the cell cycle regulatory cascade, which could result in a loss of cell cycle control. The aim of the present study was to examine in more detail the prevalence and role of the promoter methylation of genes with a proven involvement in the cell cycle regulation of pituitary adenomas, since their tumorigenesis has not yet been clearly defined. We profiled the CpG island methylation status of a series of well-characterized cell cycle regulation genes: the RB1, p14(ARF), p15(INK4b), p16(INK4a), p21(Waf1/Cip1), p27(Kip1), and p73 genes, in 34 pituitary adenomas as determined by a methylation-specific polymerase chain reaction assay. Promoter hypermethylation of the RB1, p14(ARF), p15(INK4b), p16(INK4a), p21(Waf1/Cip1), p27(Kip1), and p73 genes was detected in 12 (35%), 2 (6%), 11 (32%), 20 (59%), 1 (3%), 0 (0%), and 4 (12%) of the adenomas, respectively. In total, 88% (30 of 34) of the adenomas displayed methylation of at least one of such cell cycle regulatory genes, especially methylation of the member genes of the RB1 pathway (29 of 34; 85%). Promoter hypermethylation of p15(INK4b) coincided with RB1 and/or p16(INK4a) methylation, whereas RB1 and p16(INK4a) methylations tended to be mutually exclusive (p = 0.0048). Furthermore, promoter hypermethylations of p14(ARF), p21(Waf1/Cip1), and p73 (not belonging to the member genes of the RB1 pathway) were also coincident with RB1 and/or p16(INK4a) methylation except in one p73 methylated case. In contrast, none of the clinicopathological features, including the cell proliferation index, was significantly correlated with any particular methylation status. Our results suggested that aberrant hypermethylation of the key cell cycle regulatory genes occurs at a relatively high frequency in pituitary adenomas, especially in RB1 pathway genes with promoter hypermethylation of the p16(INK4a) gene being the most common deregulation. We further obtained evidence to indicate that RB1 and p16(INK4a) methylations tended to be mutually exclusive, but did occasionally coincide with other cell cycle regulation gene methylations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216555     DOI: 10.1007/s11060-006-9316-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  66 in total

1.  Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders.

Authors:  Norihiko Kawamata; Naoko Inagaki; Sachiko Mizumura; Kei-Ji Sugimoto; Sakura Sakajiri; Mutsuko Ohyanagi-Hara; Kazuo Oshimi
Journal:  Eur J Haematol       Date:  2005-05       Impact factor: 2.997

2.  Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation.

Authors:  S Kawano; C W Miller; A F Gombart; C R Bartram; Y Matsuo; H Asou; A Sakashita; J Said; E Tatsumi; H P Koeffler
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

3.  The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.

Authors:  Akiyoshi Ogino; Atsuo Yoshino; Yoichi Katayama; Takao Watanabe; Takashi Ota; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neuropathol Exp Neurol       Date:  2005-05       Impact factor: 3.685

Review 4.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

5.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Authors:  M L Fero; M Rivkin; M Tasch; P Porter; C E Carow; E Firpo; K Polyak; L H Tsai; V Broudy; R M Perlmutter; K Kaushansky; J M Roberts
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

Review 6.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

7.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

Review 8.  Molecular foundations of cancer: new targets for intervention.

Authors:  J E Karp; S Broder
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

9.  Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas.

Authors:  María J García; Beatriz Martínez-Delgado; Arancha Cebrian; Angel Martínez; Javier Benítez; Carmen Rivas
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

10.  Clinically nonfunctioning pituitary tumors are monoclonal in origin.

Authors:  J M Alexander; B M Biller; H Bikkal; N T Zervas; A Arnold; A Klibanski
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more
  25 in total

1.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 2.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

4.  Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis.

Authors:  Audrey Roussel-Gervais; Steve Bilodeau; Sophie Vallette; France Berthelet; André Lacroix; Dominique Figarella-Branger; Thierry Brue; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2010-07-21

5.  Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.

Authors:  Matthew Miller; Shenglin Chen; Jeffrey Woodliff; Sanjay Kansra
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 6.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

7.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

8.  Expression of p18(INK4C) is down-regulated in human pituitary adenomas.

Authors:  M Golam Hossain; Takeo Iwata; Noriko Mizusawa; Zhi Rong Qian; Shahidan Wan Nazatul Shima; Toru Okutsu; Shozo Yamada; Toshiaki Sano; Katsuhiko Yoshimoto
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 10.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.